A tumour-associated antigen expression in human haematological malignancies.
Objective responses obtained with high-dose in vivo recombinant interleukin 2 (r-IL2) in some leukaemic patients suggest among other hypotheses that blasts might express tumour rejection antigens potentially recognized by cytolytic T lymphocytes. Such antigens have been described in human melanomas and the MAGE-1 gene, coding for a tumour rejection antigen was recently identified. This gene is expressed in various solid tumours, but not in normal cells. We have screened a panel of haematological malignancies by reverse transcription and PCR and we report that MAGE-1 is not expressed in the blasts from 48 patients whereas three cell lines derived from leukaemias express this gene.
Chambost
H
H
INSERM U119, Marseille, France.
Brasseur
F
F
Coulie
P
P
de Plaen
E
E
Stoppa
A M
AM
Baume
D
D
Mannoni
P
P
Boon
T
T
Maraninchi
D
D
Olive
D
D
D000951:Antigens, Neoplasm / Q000235:genetics*; D001483:Base Sequence; D015870:Gene Expression / Q000502:physiology; D006801:Humans; D007938:Leukemia / Q000235:genetics* / Q000276:immunology; D058950:Melanoma-Specific Antigens; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis; D014158:Transcription, Genetic; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; C072011:MAGEA1 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D012333:RNA, Messenger